Aztreonam

• CAT Number: A000282
• CAS Number: 78110-38-0
• Molecular Formula: C13H17N5O8S2
• Molecular Weight: 435.40
• Purity: ≥95%
• Synonyms: Azactam; Azthreonam; Primbactam; 78110-38-0; Cayston
• Target: Antibiotic
• Solubility: >18.9mg/mL in DMSO
• Storage: -20°C
• IUPAC Name: 2-[(Z)-[1-(2-amino-1,3-thiazol-4-yl)-2-[[(2S,3S)-2-methyl-4-oxo-1-sulfoazetidin-3-yl]amino]-2-oxoethylidene]amino]oxy-2-methylpropanoic acid
• InChI: InChI=1S/C13H17N5O8S2/c1-5-7(10(20)18(5)28(23,24)25)16-9(19)8(6-4-27-12(14)15-6)17-26-13(2,3)11(21)22/h4-5,7H,1-3H3,(H2,14,15)(H,16,19)(H,21,22)(H,23,24,25)/b17-8-/t5-,7-/m0/s1
• InChIKey: WZPBZJONDBGPKJ-VEHQQRBSSA-N
• SMILES: C[C@H]1[C@@H](C(=O)N1S(=O)(=O)O)NC(=O)/C(=N\OC(C)(C)C(=O)O)/C2=CSC(=N2)N

Aztreonam（Cat No.:A000282）is a monobactam antibiotic effective against gram-negative bacteria, including Pseudomonas aeruginosa, by targeting and inhibiting bacterial cell wall synthesis. Unlike other beta-lactam antibiotics, it shows minimal cross-reactivity with penicillins, making it suitable for patients with penicillin allergies. Aztreonam is commonly used to treat respiratory, urinary tract, and intra-abdominal infections, particularly those caused by drug-resistant bacteria. In research, it aids in exploring antibiotic resistance and beta-lactamase inhibition. Its narrow-spectrum activity and beta-lactamase stability make it a valuable tool in combating gram-negative bacterial infections.

Reference

1: Jorth P, McLean K, Ratjen A, Secor PR, Bautista GE, Ravishankar S, Rezayat A,
Garudathri J, Harrison JJ, Harwood RA, Penewit K, Waalkes A, Singh PK, Salipante
SJ. Evolved Aztreonam Resistance Is Multifactorial and Can Produce Hypervirulence
in Pseudomonas aeruginosa. MBio. 2017 Oct 31;8(5). pii: e00517-17. doi:
10.1128/mBio.00517-17. PubMed PMID: 29089424; PubMed Central PMCID: PMC5666152.

2: Sader HS, Mendes RE, Pfaller MA, Shortridge D, Flamm RK, Castanheira M.
Antimicrobial Activity of Aztreonam-Avibactam and Comparator Agents Tested
against Contemporary (2016) Clinical Enterobacteriaceae Isolates. Antimicrob
Agents Chemother. 2017 Oct 23. pii: AAC.01856-17. doi: 10.1128/AAC.01856-17.
[Epub ahead of print] PubMed PMID: 29061754.

3: Thomson GK, Ayaz M, Lutes K, Thomson KS. An Improved ESBL Detection Test
Utilizing Aztreonam + Clavulanate. J Clin Microbiol. 2017 Oct 18. pii:
JCM.01309-17. doi: 10.1128/JCM.01309-17. [Epub ahead of print] PubMed PMID:
29046407.

4: Rodríguez A, Cabrera M, Reyes LF, Bodí M, Trefler S, Canadell L, Barahona D,
Ehrmann S, Martin-Loeches I, Restrepo MI, Vecellio L. In vitro evaluation of
aerosol delivery of aztreonam lysine (AZLI): an adult mechanical ventilation
model. Expert Opin Drug Deliv. 2017 Dec;14(12):1447-1453. doi:
10.1080/17425247.2017.1393411. Epub 2017 Oct 23. PubMed PMID: 29041861.

5: Pullman J, Gardovskis J, Farley B, Sun E, Quintas M, Lawrence L, Ling R,
Cammarata S; PROCEED Study Group. Efficacy and safety of delafloxacin compared
with vancomycin plus aztreonam for acute bacterial skin and skin structure
infections: a Phase 3, double-blind, randomized study. J Antimicrob Chemother.
2017 Oct 5. doi: 10.1093/jac/dkx329. [Epub ahead of print] PubMed PMID: 29029278.

6: Lohans CT, Brem J, Schofield CJ. New Delhi metallo-β-lactamase-1 catalyses
avibactam and aztreonam hydrolysis. Antimicrob Agents Chemother. 2017 Oct 2. pii:
AAC.01224-17. doi: 10.1128/AAC.01224-17. [Epub ahead of print] PubMed PMID:
28971873.

7: Mojica MF, Papp-Wallace KM, Taracila MA, Barnes MD, Rutter JD, Jacobs MR,
LiPuma JJ, Walsh TJ, Vila AJ, Bonomo RA. Avibactam Restores the Susceptibility of
Clinical Isolates of Stenotrophomonas maltophilia to Aztreonam. Antimicrob Agents
Chemother. 2017 Sep 22;61(10). pii: e00777-17. doi: 10.1128/AAC.00777-17. Print
2017 Oct. PubMed PMID: 28784669; PubMed Central PMCID: PMC5610502.

8: Karlowsky JA, Kazmierczak KM, de Jonge BLM, Hackel MA, Sahm DF, Bradford PA.
In Vitro Activity of Aztreonam-Avibactam against Enterobacteriaceae and
Pseudomonas aeruginosa Isolated by Clinical Laboratories in 40 Countries from
2012 to 2015. Antimicrob Agents Chemother. 2017 Aug 24;61(9). pii: e00472-17.
doi: 10.1128/AAC.00472-17. Print 2017 Sep. PubMed PMID: 28630192; PubMed Central
PMCID: PMC5571336.

9: Davido B, Fellous L, Lawrence C, Maxime V, Rottman M, Dinh A.
Ceftazidime-Avibactam and Aztreonam, an Interesting Strategy To Overcome β-Lactam
Resistance Conferred by Metallo-β-Lactamases in Enterobacteriaceae and
Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2017 Aug 24;61(9). pii:
e01008-17. doi: 10.1128/AAC.01008-17. Print 2017 Sep. PubMed PMID: 28630191;
PubMed Central PMCID: PMC5571320.

10: Wenzler E, Deraedt MF, Harrington AT, Danizger LH. Synergistic activity of
ceftazidime-avibactam and aztreonam against serine and
metallo-β-lactamase-producing gram-negative pathogens. Diagn Microbiol Infect
Dis. 2017 Aug;88(4):352-354. doi: 10.1016/j.diagmicrobio.2017.05.009. Epub 2017
May 18. PubMed PMID: 28602518.